TY - JOUR

T1 - Genetic Risk Factors for the Development of COVID-19 Coronavirus Infection

AU - Glotov, O. S.

AU - Chernov, A. N.

AU - Scherbak, S. G.

AU - Baranov, V. S.

N1 - Publisher Copyright: © 2021, Pleiades Publishing, Inc.

PY - 2021/8/1

Y1 - 2021/8/1

N2 - Abstract: The COVID-19 coronavirus pandemic has spread to 215 countries around the world and caused tens of millions of infections and more than a million deaths worldwide. In the midst of COVID-19 infection, it is extremely important to identify new protein and gene targets that may be highly sensitive diagnostic and prognostic markers of the severity and outcome of the disease for combating this pandemic. Identification of individual genetic predisposition allows personalizing programs of medical rehabilitation and therapy. It has now been shown that the transmissibility and severity of COVID-19 infection can be affected by gene variants in both the human body (ACE2, HLA-B*4601, FcγRIIA, MBL, TMPRSS2, TNFA, IL6, blood group A antigen, etc.) and the virus itself (ORF8 in RNA polymerase, ORF6 in RNA primase, S, N, E proteins). The presence of mutations in the proteins of the virus can change the affinity and specificity for the binding of targeted drugs to them, being the molecular basis of individual differences in the response of the human body to antiviral drugs and/or vaccines. The review summarizes the data on the variants of the genomes of the coronavirus and humans associated with an individual predisposition to an increased or decreased risk of transmission, severity, and outcome of COVID-19 infection. Targeted drugs and vaccines being developed for the therapy of COVID-19 infection are briefly reviewed.

AB - Abstract: The COVID-19 coronavirus pandemic has spread to 215 countries around the world and caused tens of millions of infections and more than a million deaths worldwide. In the midst of COVID-19 infection, it is extremely important to identify new protein and gene targets that may be highly sensitive diagnostic and prognostic markers of the severity and outcome of the disease for combating this pandemic. Identification of individual genetic predisposition allows personalizing programs of medical rehabilitation and therapy. It has now been shown that the transmissibility and severity of COVID-19 infection can be affected by gene variants in both the human body (ACE2, HLA-B*4601, FcγRIIA, MBL, TMPRSS2, TNFA, IL6, blood group A antigen, etc.) and the virus itself (ORF8 in RNA polymerase, ORF6 in RNA primase, S, N, E proteins). The presence of mutations in the proteins of the virus can change the affinity and specificity for the binding of targeted drugs to them, being the molecular basis of individual differences in the response of the human body to antiviral drugs and/or vaccines. The review summarizes the data on the variants of the genomes of the coronavirus and humans associated with an individual predisposition to an increased or decreased risk of transmission, severity, and outcome of COVID-19 infection. Targeted drugs and vaccines being developed for the therapy of COVID-19 infection are briefly reviewed.

KW - coronavirus infection

KW - COVID-19

KW - COVID-19 vaccines

KW - drugs

KW - genes

KW - polymorphisms

KW - susceptibility to coronavirus infection

KW - VIRUS

KW - PROTEIN

KW - SUSCEPTIBILITY

KW - RECEPTOR

KW - IDENTIFICATION

KW - ACE2

KW - POLYMORPHISMS

KW - ASSOCIATION

KW - SARS-CORONAVIRUS

KW - SPIKE GLYCOPROTEIN

UR - http://www.scopus.com/inward/record.url?scp=85114193945&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/17703800-f64b-32ef-9e41-e29443f8a877/

U2 - 10.1134/S1022795421080056

DO - 10.1134/S1022795421080056

M3 - Review article

AN - SCOPUS:85114193945

VL - 57

SP - 878

EP - 892

JO - Russian Journal of Genetics

JF - Russian Journal of Genetics

SN - 1022-7954

IS - 8

ER -